ClinicalTrials.gg
RecruitingNCT06162221Updated Oct 19, 2026

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

A Phase 1/2 interventional study of RMC-6291 and RMC-6236 in Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC and KRAS G12C-mutated Solid Tumors, Lung Cancer, sponsored by Revolution Medicines, Inc.. Recruiting at 98 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Revolution Medicines, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.
Updated Oct 19, 2026Site recruiting status changed6 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
616
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. — 8 open to participants now, 9 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Revolution Medicines, Inc..

Planned enrollment
2nd of 13
616 · median 430
Started
2024
the only one that year
Phase 1/2
5 of 13
4 open now
Registered
9th of 13
by date

Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc., this one is the 2nd largest by planned enrollment, is the only one that started in 2024, is one of 5 in phase 1/2, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc., or all of them as a file.
02

Study summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.

The first four subprotocols include the following:

Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Read the detailed description

The platform study design allows combinations of RAS(ON) inhibitors with other anticancer agents or as a monotherapy to be evaluated in patients with RAS-mutated solid tumors with a focus on NSCLC.

This is an open-label platform Phase 1b/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC), or as a monotherapy and to define the Recommended Phase 2 Dose and Schedule (RP2DS). Enrollment of patients with KRAS or RAS mutations will be specified in each subprotocol.

Subprotocol A is an open-label, multicenter, Phase 1b/2 study of RMC-6291, with or without RMC-6236, in combination with pembrolizumab, with or without chemotherapy, in patients with KRAS G12C-mutated advanced solid tumors.

Subprotocol B is an open-label, multicenter, Phase1b/2 study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in patients with RAS-mutated non-small cell lung cancer (NSCLC)

Subprotocol C is an open-label, multicenter, Phase1b/2 study of RMC-9805 with or without RMC-6236, in combination with other anticancer agents, in patients with RAS G12D-mutated non-small cell lung cancer (NSCLC)

Subprotocol D is a Phase 2, Open-label, Multicenter Study of Zoldonrasib (RMC-9805) in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)

Subprotocols A, B, and C consist of two parts: Part 1 - Dose Exploration and Part 2 - Dose Expansion. Subprotocol D consists of only one part.

03

Conditions studied

  • Non-Small Cell Lung Cancer, NSCLC
  • KRAS, NRAS, HRAS-mutated NSCLC
  • KRAS G12C-mutated Solid Tumors, Lung Cancer
  • Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
  • RAS G12D-mutated NSCLC

Keywords

  • NSCLC
  • KRAS G12C
  • RAS Mutation
  • KRAS G12X
  • Non-Small Cell Lung Cancer
  • Lung Cancer
  • Lung Cancer Stage IV
  • Advanced Solid Tumor
  • Cancer
  • RAS G12D
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Patients (unless otherwise noted):

  • ≥ 18 years of age
  • PS is 0 to 1
  • Adequate organ function as outlined by the study
  • Received prior standard therapy appropriate for tumor type and stage
  • Must have documented, locally advanced or KRAS G12C-mutated solid tumor (not amenable to curative surgery) (Subprotocol A)
  • Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
  • Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)

Exclusion criteria

Exclusion criteria:

All Patients:

  • Primary central nervous system (CNS) tumors
  • Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
  • Major surgery \< 28 days of first dose
  • Active or history of interstitial lung disease (ILD) or pneumonitis requiring

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
616 participants (estimated)

Study arms

  • Experimental
    Subprotocol A: KRAS G12C-Mutated Solid Tumors

    RMC-6291 (BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)

    Drug: RMC-6291 · Drug: RMC-6236 · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Subprotocol B: RAS-mutated NSCLC

    RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)

    Drug: RMC-6236 · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Subprotocol C: RAS G12D-mutated NSCLC

    RMC-9805 (QD or BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W).

    Drug: RMC-6236 · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Drug: RMC-9805

  • Experimental
    Subprotocol D: RAS G12D-mutated NSCLC

    RMC-9805 (QD)

    Drug: RMC-9805

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs and vital signs

    Time frame: Up to 5 years

  2. Dose limiting toxicities

    Number of participants with dose limiting toxicities

    Time frame: 21 days

Secondary outcomes

  1. Drug concentrations over time

    Observed blood concentration of each drug as applicable per subprotocol

    Time frame: Up to 21 weeks

  2. Cmax

    Maximum observed blood concentration of each drug as applicable per subprotocol

    Time frame: Up to 21 weeks

  3. Tmax

    Time to reach maximum blood concentration of each drug as applicable per subprotocol

    Time frame: Up to 21 weeks

  4. AUC

    Area under the concentration-time curve of each drug as applicable per subprotocol

    Time frame: Up to 21 weeks

  5. ORR

    Objective Response Rate per RECIST v1.1

    Time frame: Up to 5 years

  6. DOR

    Duration of Response per RECIST v1.1

    Time frame: Up to 5 years

07

Study locations

53 of 98 sites recruiting
08

References and documents

Publications

  • Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8. PubMed 40056080 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 41 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 8, 2023
StartActual
Jan 18, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 1 site removed. 39 sites changed recruiting status (39 now active, not recruiting)
Show 39 sites
  • City of Hope - Duarte · Duarte, United StatesRecruiting→Active, not recruiting
  • City of Hope - Lennar · Irvine, United StatesRecruiting→Active, not recruiting
  • Cancer Specialists of North Florida · Saint Augustine, United StatesRecruiting→Active, not recruiting
  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) · Detroit, United StatesRecruiting→Active, not recruiting
  • Intermountain Health - St. Vincent Frontier Cancer Center · Billings, United StatesRecruiting→Active, not recruiting
  • Icahn School of Medicine at Mount Sinai · New York, United StatesRecruiting→Active, not recruiting
  • Clinical Research Alliance · Westbury, United StatesRecruiting→Active, not recruiting
  • Fred Hutchinson Cancer Research Center · Seattle, United StatesRecruiting→Active, not recruiting
  • Chris O'Brien Lifehouse Hosptial · Camperdown, AustraliaRecruiting→Active, not recruiting
  • Liverpool Hospital · Liverpool, AustraliaRecruiting→Active, not recruiting
  • Royal North Shore Hospital · St Leonards, AustraliaRecruiting→Active, not recruiting
  • Monash Health · Clayton, AustraliaRecruiting→Active, not recruiting
  • Linear Clinical Research · Nedlands, AustraliaRecruiting→Active, not recruiting
  • Universitätsklinikum St. Pölten · Sankt Pölten, AustriaRecruiting→Active, not recruiting
  • Nemocnice AGEL Novy Jicin a.s · Nový Jičín, CzechiaRecruiting→Active, not recruiting
  • CHU de Nantes · Nantes, FranceRecruiting→Active, not recruiting
  • Ambroise-Paré Hospital · Boulogne, FranceRecruiting→Active, not recruiting
  • Hopital Tenon - AP-HP · Paris, FranceRecruiting→Active, not recruiting
  • Hopital Foch · Suresnes, FranceRecruiting→Active, not recruiting
  • Lungenfachklinik Immenhausen · Immenhausen, GermanyRecruiting→Active, not recruiting
  • Krankenhaus Bethanien Moers · Moers, GermanyRecruiting→Active, not recruiting
  • Henry Dunant Hospital Center · Athens, GreeceRecruiting→Active, not recruiting
  • Thoracic General Hospital of Athens "I SOTIRIA" · Athens, GreeceRecruiting→Active, not recruiting
  • ASST Grande Ospedale Metropolitano Niguarda · Milan, ItalyRecruiting→Active, not recruiting
  • A.O.U. San Luigi Gonzaga-Orbassano - SCDU Oncologia Medica · Orbassano, ItalyRecruiting→Active, not recruiting
  • IRCCS Instituto Nazionale tumori Ragina Elena · Rome, ItalyRecruiting→Active, not recruiting
  • Fondazione Policlinico Universitario A Gemelli-Rome · Rome, ItalyRecruiting→Active, not recruiting
  • University Medical Centre Groningen · Groningen, NetherlandsRecruiting→Active, not recruiting
  • Samsung Medical Center · Seoul, South KoreaRecruiting→Active, not recruiting
  • National Cancer Center · Goyang-si, South KoreaRecruiting→Active, not recruiting
  • …and 9 more on the registry record
Show 6 added (2 United States, 1 Austria, 1 Greece, 1 Italy, 1 Spain)
  • University of California Los Angeles · Los Angeles, United States
  • Kaiser Permanente · Vallejo, United States
  • Wiener Gesundheitsverbund - Klinik Floridsdorf · Vienna, Austria
  • General Hospital of Thessaloniki · Thessaloniki, Greece
  • Instituto Europeo Di Oncologia · Milan, Italy
  • Hospital Universitario Quironsalud - NEXT Oncology, Madrid · Madrid, Spain
Show 1 removed
  • Colorado Health Medical Group - Medical Oncology & Hematology · Colorado Springs, United States
Oct 19, 2026
Site contacts
Changed at 14 sites. See the sites
Show 14 sites
  • City of Hope - Duarte · Duarte, United StatesContact removed t•••@coh.org · •••3411
  • City of Hope - Lennar · Irvine, United StatesContact removed s•••@coh.org · •••9785
  • Cancer Specialists of North Florida · Saint Augustine, United StatesContact removed J•••@csnf.us · •••4488
  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) · Detroit, United StatesContact removed d•••@hfhs.org · •••7518
  • Intermountain Health - St. Vincent Frontier Cancer Center · Billings, United StatesContact removed p•••@imail.org · •••6290
  • Icahn School of Medicine at Mount Sinai · New York, United StatesContact removed j•••@mssm.edu · •••2293
  • Clinical Research Alliance · Westbury, United StatesContact removed •••2918
  • CHU de Nantes · Nantes, FranceContact removed J•••@chu-nantes.fr · •••5930
  • Hopital Foch · Suresnes, FranceContact removed j•••@hopital-foch.com · •••2463
  • Lungenfachklinik Immenhausen · Immenhausen, GermanyContact removed s•••@lungenfachklinik-immenhausen.de · •••1210
  • Krankenhaus Bethanien Moers · Moers, GermanyContact removed s•••@bethanienmoers.de · •••2205
  • ASST Grande Ospedale Metropolitano Niguarda · Milan, ItalyContact removed o•••@ospedaleniguarda.it · •••2291
  • IRCCS Instituto Nazionale tumori Ragina Elena · Rome, ItalyContact removed o•••@irst.emr.it
  • Fondazione Policlinico Universitario A Gemelli-Rome · Rome, ItalyContact removed f•••@policlinicogemelli.it
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    6 sites added, 1 site removed. 39 sites changed recruiting status (39 now active, not recruiting)
    Show 39 sites
    • City of Hope - Duarte · Duarte, United StatesRecruiting→Active, not recruiting
    • City of Hope - Lennar · Irvine, United StatesRecruiting→Active, not recruiting
    • Cancer Specialists of North Florida · Saint Augustine, United StatesRecruiting→Active, not recruiting
    • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) · Detroit, United StatesRecruiting→Active, not recruiting
    • Intermountain Health - St. Vincent Frontier Cancer Center · Billings, United StatesRecruiting→Active, not recruiting
    • Icahn School of Medicine at Mount Sinai · New York, United StatesRecruiting→Active, not recruiting
    • Clinical Research Alliance · Westbury, United StatesRecruiting→Active, not recruiting
    • Fred Hutchinson Cancer Research Center · Seattle, United StatesRecruiting→Active, not recruiting
    • Chris O'Brien Lifehouse Hosptial · Camperdown, AustraliaRecruiting→Active, not recruiting
    • Liverpool Hospital · Liverpool, AustraliaRecruiting→Active, not recruiting
    • Royal North Shore Hospital · St Leonards, AustraliaRecruiting→Active, not recruiting
    • Monash Health · Clayton, AustraliaRecruiting→Active, not recruiting
    • Linear Clinical Research · Nedlands, AustraliaRecruiting→Active, not recruiting
    • Universitätsklinikum St. Pölten · Sankt Pölten, AustriaRecruiting→Active, not recruiting
    • Nemocnice AGEL Novy Jicin a.s · Nový Jičín, CzechiaRecruiting→Active, not recruiting
    • CHU de Nantes · Nantes, FranceRecruiting→Active, not recruiting
    • Ambroise-Paré Hospital · Boulogne, FranceRecruiting→Active, not recruiting
    • Hopital Tenon - AP-HP · Paris, FranceRecruiting→Active, not recruiting
    • Hopital Foch · Suresnes, FranceRecruiting→Active, not recruiting
    • Lungenfachklinik Immenhausen · Immenhausen, GermanyRecruiting→Active, not recruiting
    • Krankenhaus Bethanien Moers · Moers, GermanyRecruiting→Active, not recruiting
    • Henry Dunant Hospital Center · Athens, GreeceRecruiting→Active, not recruiting
    • Thoracic General Hospital of Athens "I SOTIRIA" · Athens, GreeceRecruiting→Active, not recruiting
    • ASST Grande Ospedale Metropolitano Niguarda · Milan, ItalyRecruiting→Active, not recruiting
    • A.O.U. San Luigi Gonzaga-Orbassano - SCDU Oncologia Medica · Orbassano, ItalyRecruiting→Active, not recruiting
    • IRCCS Instituto Nazionale tumori Ragina Elena · Rome, ItalyRecruiting→Active, not recruiting
    • Fondazione Policlinico Universitario A Gemelli-Rome · Rome, ItalyRecruiting→Active, not recruiting
    • University Medical Centre Groningen · Groningen, NetherlandsRecruiting→Active, not recruiting
    • Samsung Medical Center · Seoul, South KoreaRecruiting→Active, not recruiting
    • National Cancer Center · Goyang-si, South KoreaRecruiting→Active, not recruiting
    • …and 9 more on the registry record
    Show 6 added (2 United States, 1 Austria, 1 Greece, 1 Italy, 1 Spain)
    • University of California Los Angeles · Los Angeles, United States
    • Kaiser Permanente · Vallejo, United States
    • Wiener Gesundheitsverbund - Klinik Floridsdorf · Vienna, Austria
    • General Hospital of Thessaloniki · Thessaloniki, Greece
    • Instituto Europeo Di Oncologia · Milan, Italy
    • Hospital Universitario Quironsalud - NEXT Oncology, Madrid · Madrid, Spain
    Show 1 removed
    • Colorado Health Medical Group - Medical Oncology & Hematology · Colorado Springs, United States
    Site contacts Changed at 14 sites. See the sites
    Show 14 sites
    • City of Hope - Duarte · Duarte, United StatesContact removed t•••@coh.org · •••3411
    • City of Hope - Lennar · Irvine, United StatesContact removed s•••@coh.org · •••9785
    • Cancer Specialists of North Florida · Saint Augustine, United StatesContact removed J•••@csnf.us · •••4488
    • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) · Detroit, United StatesContact removed d•••@hfhs.org · •••7518
    • Intermountain Health - St. Vincent Frontier Cancer Center · Billings, United StatesContact removed p•••@imail.org · •••6290
    • Icahn School of Medicine at Mount Sinai · New York, United StatesContact removed j•••@mssm.edu · •••2293
    • Clinical Research Alliance · Westbury, United StatesContact removed •••2918
    • CHU de Nantes · Nantes, FranceContact removed J•••@chu-nantes.fr · •••5930
    • Hopital Foch · Suresnes, FranceContact removed j•••@hopital-foch.com · •••2463
    • Lungenfachklinik Immenhausen · Immenhausen, GermanyContact removed s•••@lungenfachklinik-immenhausen.de · •••1210
    • Krankenhaus Bethanien Moers · Moers, GermanyContact removed s•••@bethanienmoers.de · •••2205
    • ASST Grande Ospedale Metropolitano Niguarda · Milan, ItalyContact removed o•••@ospedaleniguarda.it · •••2291
    • IRCCS Instituto Nazionale tumori Ragina Elena · Rome, ItalyContact removed o•••@irst.emr.it
    • Fondazione Policlinico Universitario A Gemelli-Rome · Rome, ItalyContact removed f•••@policlinicogemelli.it

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06162221
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Jan 18, 2024
Primary completion
Jun 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Revolution Medicines
Contact
medinfo@RevMed.com
1-844-2-REVMED
Revolution Medicines
study director · Revolution Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elironrasib · Daraxonrasib · Zoldonrasib

Start the discussion